Press Releases May 11, 2026 04:33 PM

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health announces secondary offering of over 31 million shares by private equity affiliates

By Hana Yamamoto SHC

Sotera Health Company, a leading global provider of sterilization and lab testing services, announced a secondary offering of 31,838,253 shares by affiliates of Warburg Pincus and GTCR. The company itself is not selling shares nor raising capital, and Goldman Sachs is the underwriter. The proceeds go to the selling shareholders, not Sotera Health.

Sotera Health Announces Secondary Offering of Common Stock
SHC

Key Points

  • Sotera Health's secondary stock offering involves 31.8 million shares sold by private equity affiliates Warburg Pincus and GTCR.
  • The company is not issuing new shares and will not receive proceeds; it will only cover offering expenses as per registration rights agreement.
  • Goldman Sachs is underwriting the offering, which is conducted through a registered prospectus under SEC regulations.

CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 31,838,253 shares of its common stock, par value $0.01 per share. All 31,838,253 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registration Rights Agreement.

Goldman Sachs & Co. LLC is acting as the underwriter for the Offering.

The Offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the Offering may be obtained, when available, from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526 or by email at [email protected].

A registration statement relating to these securities was filed with the Securities and Exchange Commission on February 27, 2024, and became effective automatically.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-looking Statements:

Statements in this press release regarding the Company that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Certain of these risks and uncertainties are described in the Company’s registration statement on Form S-3 filed with the SEC, including under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements,” under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K. Forward-looking statements made in this release speak only as of the date of this release, and the Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances, except as required by law.

About Sotera Health:

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

INVESTOR RELATIONS CONTACT:

Jason Peterson
Vice President, Investor Relations, Sotera Health
[email protected]

MEDIA CONTACT:

Kristin Gibbs
Chief Marketing Officer, Sotera Health
[email protected]

Source: Sotera Health Company


Risks

  • The secondary offering may dilute the market for existing shares and increase share supply, potentially affecting share price volatility.
  • Uncertainties inherent to forward-looking statements about the company's business and market conditions remain, as noted in its SEC filings.
  • The sale by private equity firms may signal upcoming shifts in ownership structure, which could impact investor sentiment.

More from Press Releases

Banzai to Host First Quarter 2026 Financial Results Conference Call on Friday, May 15, 2026 at 4:30 p.m. Eastern Time May 12, 2026 Agora, Inc. to Report First Quarter 2026 Financial Results on May 26, 2026 May 12, 2026 Auburn National Bancorporation, Inc. Declares Quarterly Dividend May 12, 2026 Highwoods Sells Bridgestone Tower in CBD Nashville May 12, 2026 Algoma Steel Group Inc. Reports Financial Results for the Three Months Ended March 31, 2026 May 12, 2026